The Race to Herd Immunity Update: China Ramps up Injections

While China is administering Covid-19 vaccine doses at a higher daily rate now, it still lags far behind the U.S. in achieving herd immunity.
Anthony RussoApr 05,2021,16:37

After months of a slow vaccine rollout, China has ramped up its efforts and has even surpassed the United States, administering at a higher daily rate.

According to data collected by Bloomberg, China has now administered nearly 137 million Covid-19 vaccine doses. That's more than double since early March.

China is now administering 4.9 million doses per day compared with the 3.1 million daily rate in the United States.

Thanks to the progress, the Chinese Center for Disease Prevention and Control last week boosted its vaccine injection target to 560 million people, representing 40% of the country’s population, by the end of June.

At the rate China is administering vaccines, Capital Economics noted it will “soon be one of the more advanced [campaigns] in the emerging world.”

“China’s vaccination campaign has accelerated sharply over the past week,” Capital Economics wrote in a report late last week.

Further, “The authorities are starting to share more regular information on the progress of the campaign too, which points to greater confidence that the target will be met.”

But still, China lags far behind the U.S. in achieving herd immunity due to its gigantic population size of nearly 1.4 billion. So far, the U.S. has administered 26 doses per 100 people compared with China’s five for every 100 individuals.

China does have one advantage: Although infections are starting to spike again, the country only saw 32 new cases of the coronavirus on Sunday, according to China’s National Health Commission. Meanwhile, the U.S. is still recording tens of thousands of new infections per day.

China now has approved five vaccines. The latest approved vaccine was jointly developed by the Chinese Academy of Sciences and Anhui Zhifei Longcom Biopharmaceutical Co. Ltd.

Topics:Chinese Academy of Sciences, Anhui Zhifei Longcom Biopharmaceutical, China, U.S.